Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for non-Crohn Anal Fistulas
2022-502263-38-00Phase 2Authorised
- Sponsor
- Aarhus University Hospital
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in anal fistula comparing Infliximab combination arm with Placebo (saline) arm (2 arms). Primary endpoint: Improvement in fistula disease enabling surgical closure. Planned start Feb 2023; status: authorised.
02
Drugs
infliximab
03
Conditions
anal fistula
Beyond the preview
Go deeper on 2022-502263-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502263-38-00.